Pds Biotechnology (PDSB) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Pds Biotechnology in October 2026.
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Pds Biotechnology (PDSB) Stock Forecast
Analyst price target, next 12 months
$10.42
+1291.7% vs today's $0.75
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Pds Biotechnology have a consensus 12-month target of $10.42, above the current price of $0.75.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying PDS Biotechnology's stock with a target price of $10.42, indicating strong growth potential.
Financial Health
PDS Biotechnology is generating modest cash flow, indicating steady operations but with room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
